Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 144

Sort by

Sort Order Select

Journal Articles

Current Treatments Do Not Improve the Prognosis of Patients with Atypical CML and Unclassified MDS/MPN. a Joint Report from Fi-LMC, FIM, Gfch and GFM

Vaidie Julien, MD, Delphine Rea, MD, Sylvain Thepot, MD, Le Pluart Bruno, MD, Nathalie Gachard, PhD, Stéphanie Struski, MD, Lydia Roy, MD, Cecile Bally, MD, Jo Caers, MD PhD, Franck E Nicolini, MD PhD, Bruno Cassinat, PharmD, PhD, Eric Lippert, MD PhD, Laurence Legros, MD PhD, Raphael Itzykson, MD PhD

Blood (2019) 134 (Supplement_1): 2954.

https://doi.org/10.1182/blood-2019-127254

Published: 2019

Journal Articles

Prospective Evaluation of ABL Kinase Domain Mutational Analysis By Next-Generation-Sequencing in Newly Diagnosed CP CML Patients Undergoing First-Line Treatment with Nilotinib Alone or Nilotinib + Pegylated Interferon-α2a in a Prospective Phase III Trial

Hugues de Lavallade, MD PhD, Sophie Jackson, BSc, Aytug Kizilors, PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnes Guerci-Bresler, MD PhD, Delphine Rea, MD, Claudine Chollet, MSc, Stephane Morisset, BioStat, Fanny Robbesyn, BSc, Francois-Xavier Mahon, MD PhD, Stephanie Dulucq, PharmD, PhD, Franck E Nicolini, MD PhD

Blood (2019) 134 (Supplement_1): 664.

https://doi.org/10.1182/blood-2019-125108

Published: 2019

Journal Articles

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Blood (2019) 134 (Supplement_1): 494.

https://doi.org/10.1182/blood-2019-123674

Published: 2019

Journal Articles

Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database

Blood (2019) 134 (Supplement_1): 498.

https://doi.org/10.1182/blood-2019-124430

Published: 2019

Journal Articles

Personalised Follow-up Program after Acute Phase of Treatment in Oncology/Hematology Patients Towards Early Intervention, Better Care and Quality of Life Improvement: Results from Pasca Pilot Study

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Romain Buono, Solene Poirey, Isabela Pascu, Emmanuelle Nicolas-Virelizier, MD, Souad Assaad, MD, Amine Belhabri, Laure Lebras, MD, Yann Guillermin, MD, Philippe Rey, MD, Lila Gilis, MD, Franck E Nicolini, MD PhD, Stephane Morisset, BioStat, Audrey Couillet, Gisele Chvetzoff, Jean-Yves Blay, MD PhD, Beatrice Fervers, Anne-Sophie Michallet, MD PhD

Blood (2019) 134 (Supplement_1): 5817.

https://doi.org/10.1182/blood-2019-130597

Published: 2019

Journal Articles

Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy

Blood (2019) 134 (Supplement_1): 4158.

https://doi.org/10.1182/blood-2019-129751

Published: 2019

Journal Articles

Clinical Spectrum, Long-Term Outcomes and Predictors of Relapse after Imatinib Discontinuation in FIP1L1-Pdgfra-Associated Chronic Eosinophilic Leukemia: Data from 150 Patients

Blood (2019) 134 (Supplement_1): 840.

https://doi.org/10.1182/blood-2019-130009

Published: 2019

Journal Articles

Fractionated Gemtuzumab Ozogamicin Combined with Intermediate-Dose Cytarabine and Daunorubicin As Salvage Therapy in Very High Risk AML Patients: A Bridge to Reduced Intensity Conditioning Transplant?

Etienne Paubelle, MD PhD, Sophie Ducastelle, MD, Helene Labussiere, MD, Franck E. Nicolini, MD PhD, Fiorenza Barraco, MD, Adriana Plesa, Gilles A. Salles, Eric Wattel, MD PhD, Xavier Thomas, MD PhD

Blood (2016) 128 (22): 4003.

https://doi.org/10.1182/blood.V128.22.4003.4003

Published: 2016

Journal Articles

Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop

Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Carla Maria Boquimpani, Naoto Takahashi, MD PhD, Noam Benyamini, MD, Nelma Cristina D Clementino, MD, Vasily Shuvaev, MD, Sikander Ailawadhi, MD, Jeffrey H. Lipton, MD PhD, Anna G Turkina, Prof., MD, Elena Beatriz Moiraghi, MD, Franck E. Nicolini, MD PhD, Jolanta Dengler, Tomasz Sacha, Dong-Wook Kim, MD PhD, Rafik Fellague-Chebra, MD MSc, Sandip Acharya, MSc, Nancy Krunic, PhD, Yu Jin, MS, François-Xavier Mahon, MD PhD

Blood (2016) 128 (22): 792.

https://doi.org/10.1182/blood.V128.22.792.792

Published: 2016

Journal Articles

Second TKI Discontinuation in CML Patients That Failed First Discontinuation and Subsequently Regained Deep Molecular Response after TKI Re-Challenge

Thomas Pagliardini, Franck E. Nicolini, MD PhD, Stephane Giraudier, MD PhD, Philippe Rousselot, Gabriel Etienne, MD PhD, Françoise Huguet, MD, Agnes Guerci-Bresler, MD PhD, Bruno R. Varet, MDPhD, Martine Escoffre, MD, Stephane Morisset, Stat, Francois-Xavier Mahon, Laurence Legros, MD PhD

Blood (2016) 128 (22): 788.

https://doi.org/10.1182/blood.V128.22.788.788

Published: 2016

Journal Articles

Characterisation of Molecular Relapse Profiles after Tyrosine Kinase Inhibitor Cessation in Patients Eligible for Treatment-Free Remission Strategies in Chronic Phase CML

Franck E Nicolini, MD PhD, Vincent Alcazer, MD, Stephanie Dulucq, PharmD, PhD, Marie Balsat, MD, Helene Labussiere, MD, Helene Lequeu, MD, Mohamad Sobh, PharmD, Stephane Morisset, Stat, Pierre Sujobert, MD PhD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2016) 128 (22): 1893.

https://doi.org/10.1182/blood.V128.22.1893.1893

Published: 2016

Journal Articles

Imatinib as Second-Line Therapy, Ameliorates or Maintains Molecular Responses Obtained with Ponatinib First-Line in Chronic Phase CML Patients

Franck E. Nicolini, MD PhD, Gaelle Fossard, MD, Valerie Coiteux, MD, Viviane Dubruille, MD, Vincent Alcazer, MD, Mohamad Sobh, PharmD, Pierre Mouchel, MD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD, Agnes Guerci, MD PhD

Blood (2016) 128 (22): 1894.

https://doi.org/10.1182/blood.V128.22.1894.1894

Published: 2016

Journal Articles

Mixed Chimerism at Three Months after Allogeneic Hematopoietic Stem Cell Transplantation Is a Significant Predictor of Disease Relapse in High-Risk Acute Myeloid Leukemia Patients in First Complete Remission

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Hélène Labussière-wallet, MD, Marie Balsat, MD, Caroline Lejeune, MD, Isabelle Mollet, Tech., Philippe Moskovtchenko, Tech., Xavier Thomas, Fiorenza Barraco, MD, Valérie Mialou, Tech., Valérie Dubois, MD, Franck E. Nicolini, MD PhD

Blood (2015) 126 (23): 2577.

https://doi.org/10.1182/blood.V126.23.2577.2577

Published: 2015

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients in First Complete Remission: Significant Impact of the Interval Between Diagnosis and Transplantation on Different Outcomes

Stéphanie Ducreux, PharmD, Mohamad Sobh, PharmD, Stéphane Morisset, Stat, Marie Balsat, MD, Xavier Thomas, Caroline Lejeune, MD, Sophie Ducastelle-Leprêtre, MD, Fiorenza Barraco, MD, Hélène Labussière-wallet, MD, Franck E. Nicolini, MD PhD, Mauricette Michallet, MD PhD, Valérie Dubois, MD

Blood (2015) 126 (23): 5517.

https://doi.org/10.1182/blood.V126.23.5517.5517

Published: 2015

Journal Articles

Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study

Blood (2015) 126 (23): 5142.

https://doi.org/10.1182/blood.V126.23.5142.5142

Published: 2015

Journal Articles

First Results of a Prospective Study on Erythropoietin Biosimilar (Epoetin zeta) Use in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Jeremy Monfray, CRA, Hélène Labussière-wallet, MD, Marie Balsat, MD, Caroline Lejeune, MD, Sophie Ducastelle-Leprêtre, MD, Fiorenza Barraco, MD, Xavier Thomas, Franck E. Nicolini, MD PhD

Blood (2015) 126 (23): 4477.

https://doi.org/10.1182/blood.V126.23.4477.4477

Published: 2015

Journal Articles

Survey of Serum Aspergillus Antigen in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia or Allogeneic Hematopoietic Stem Cell Transplantation: Role in Predicting Invasive Aspergillosis and in Modifying the Therapeutic Strategy

Van Hung Tran, PhD, Florence Persat, MD, Sophie Gardes, MD, Jeremy Monfray, CRA, Sophie Ducastelle-Leprêtre, MD, Damien Dupont, Mohamad Sobh, PharmD, Fiorenza Barraco, MD, Hélène Labussière-Wallet, MD, Xavier Thomas, Franck E. Nicolini, MD PhD, Caroline Lejeune, MD, Marie Balsat, MD, René Ecochard, MD PhD, Mauricette Michallet, MD PhD

Blood (2015) 126 (23): 3428.

https://doi.org/10.1182/blood.V126.23.3428.3428

Published: 2015

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Peripheral Blood or Bone Marrow Donors: The Impact of HLA Matching Including HLA-DPB1 Allele in a Multivariable Risk Model

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Hélène Labussière-wallet, MD, Marie Balsat, MD, Caroline Lejeune, MD, Sophie Ducastelle-Leprêtre, MD, Xavier Thomas, Catherine Giannoli, Philippe Moskovtchenko, Tech., Fiorenza Barraco, MD, Franck E. Nicolini, MD PhD, Valérie Dubois, MD

Blood (2015) 126 (23): 3213.

https://doi.org/10.1182/blood.V126.23.3213.3213

Published: 2015

Journal Articles

The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation

Franck E. Nicolini, MD PhD, Grzegorz W. Basak, MD PhD, Dong-Wook Kim, MD PhD, Eduardo Olavarria, MD PhD, Javier Pinilla-Ibarz, MD PhD, Jane F. Apperley, MD, Timothy P. Hughes, MD, Dietger Niederwieser, MD, Michael J. Mauro, MD, Charles Chuah, MD PhD, Andreas Hochhaus, MD, Giovanni Martinelli, MD PhD, Maral DerSarkissian, PhD, Andrew Kageleiry, BS, Mo Yang, PhD, Hui Huang, MBA, PhD, Lisa J. McGarry, MPH, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 480.

https://doi.org/10.1182/blood.V126.23.480.480

Published: 2015

Journal Articles

Long-Term Follow-up of the French 1 Stop Imatinib Study (STIM1) in Chronic Myeloid Leukemia Patients

Gabriel Etienne, MD PhD, Delphine Rea, MD PhD, Joelle Guilhot, PhD, Francois Guilhot, MD, Françoise Huguet, MD, Laurence Legros, MD, Franck E. Nicolini, MD PhD, Aude Charbonnier, Agnes Guerci, MD, Bruno R. Varet, MD, Philippe Rousselot, MD PhD Professor, Francois Xavier Mahon, MD PhD

Blood (2015) 126 (23): 345.

https://doi.org/10.1182/blood.V126.23.345.345

Published: 2015

NARROW

Current Treatments Do Not Improve the Prognosis of Patients with Atypical CML and Unclassified MDS/MPN. a Joint Report from Fi-LMC, FIM, Gfch and GFM

Prospective Evaluation of ABL Kinase Domain Mutational Analysis By Next-Generation-Sequencing in Newly Diagnosed CP CML Patients Undergoing First-Line Treatment with Nilotinib Alone or Nilotinib + Pegylated Interferon-α2a in a Prospective Phase III Trial

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database

Personalised Follow-up Program after Acute Phase of Treatment in Oncology/Hematology Patients Towards Early Intervention, Better Care and Quality of Life Improvement: Results from Pasca Pilot Study

Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy

Clinical Spectrum, Long-Term Outcomes and Predictors of Relapse after Imatinib Discontinuation in FIP1L1-Pdgfra-Associated Chronic Eosinophilic Leukemia: Data from 150 Patients

Fractionated Gemtuzumab Ozogamicin Combined with Intermediate-Dose Cytarabine and Daunorubicin As Salvage Therapy in Very High Risk AML Patients: A Bridge to Reduced Intensity Conditioning Transplant?

Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop

Second TKI Discontinuation in CML Patients That Failed First Discontinuation and Subsequently Regained Deep Molecular Response after TKI Re-Challenge

Characterisation of Molecular Relapse Profiles after Tyrosine Kinase Inhibitor Cessation in Patients Eligible for Treatment-Free Remission Strategies in Chronic Phase CML

Imatinib as Second-Line Therapy, Ameliorates or Maintains Molecular Responses Obtained with Ponatinib First-Line in Chronic Phase CML Patients

Mixed Chimerism at Three Months after Allogeneic Hematopoietic Stem Cell Transplantation Is a Significant Predictor of Disease Relapse in High-Risk Acute Myeloid Leukemia Patients in First Complete Remission

Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients in First Complete Remission: Significant Impact of the Interval Between Diagnosis and Transplantation on Different Outcomes

Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study

First Results of a Prospective Study on Erythropoietin Biosimilar (Epoetin zeta) Use in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Survey of Serum Aspergillus Antigen in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia or Allogeneic Hematopoietic Stem Cell Transplantation: Role in Predicting Invasive Aspergillosis and in Modifying the Therapeutic Strategy

Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Peripheral Blood or Bone Marrow Donors: The Impact of HLA Matching Including HLA-DPB1 Allele in a Multivariable Risk Model

The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation

Long-Term Follow-up of the French 1 Stop Imatinib Study (STIM1) in Chronic Myeloid Leukemia Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only